Saturday 17 October 2026
Export ADAPY’s income statement to Excel — free account
Adaptimmune Therapeutics PLC
ADAPY Healthcare Biotechnology
Adaptimmune Therapeutics PLC’s revenue for fiscal 2025 (year ended December 2025) was $5.9 million, down 96.7% from fiscal 2024. In the quarter to June 2025, revenue fell 89.3%, EPS fell 140.7% and free cash flow fell 174.7%, each against the same quarter a year earlier.
0.03
0.00
0.00%
Follow ADAPY
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 3 | 1 | 5 | 5 | 2 | 3 | 4 | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
1.40 | 3.21 | 9.77 | (4.17) | 2.36 | (1.11) | (4.16) | (5.52) | (6.11) | (23.33) |
P/S ratio |
20.54 | 16.50 | 9.41 | 48.43 | 194.01 | 95.02 | 9.92 | 2.50 | 0.77 | 0.12 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 299.93 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
2.65 | 1.75 | 7.83 | (8.00) | 2.26 | (1.74) | (8.21) | (11.83) | (14.09) | (51.29) |
P/Operating CF |
123.05 | (29.24) | (17.67) | (10.05) | (26.28) | 4.36 | 131.84 | (10.28) | (4.52) | (0.23) |
Beneish M-Score |
— | (2.20) | (2.02) | 5,239.88 | (1.90) | (1.49) | 1.53 | (1.62) | 1.68 | 16.71 |
P/B ratio |
1.76 | 3.08 | 2.27 | 1.02 | 2.25 | 2.84 | 3.29 | 3.82 | 10.45 | 0.00 |
Price to Tangible BV |
1.77 | 3.10 | 2.28 | 1.04 | 2.26 | 2.85 | 3.31 | 3.85 | 30.18 | 0.00 |
EV/Sales |
7.76 | 11.00 | 5.96 | 22.83 | 106.27 | 38.68 | 3.13 | 0.40 | 0.20 | 0.12 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.44 | 0.00 |
EV/Operating CF |
(2.29) | (7.66) | (3.40) | (0.53) | (7.85) | 22.17 | (0.60) | (0.17) | (0.50) | (0.04) |
EV/FCF |
(1.81) | (5.28) | (3.25) | (0.51) | (7.44) | 122.09 | (0.50) | (0.17) | (0.49) | (0.04) |
Quick Ratio |
4.54 | 2.81 | 8.40 | 3.21 | 9.43 | 5.92 | 3.29 | 2.03 | 2.56 | 1.64 |
Current Ratio |
4.94 | 3.10 | 9.46 | 3.51 | 10.19 | 6.64 | 3.96 | 2.85 | 2.88 | 2.04 |
Net Debt/EBITDA |
2.61 | 2.77 | 2.75 | 0.51 | 2.76 | 2.23 | 1.17 | 1.13 | 0.61 | 0.47 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 12.65% | 4.64% | 4.93% | 6.19% | 0.00% | 20.39% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.19 | 0.06 | 0.11 | 0.25 | 0.00 | 3.85 | 0.00 |
Asset Turnover |
0.05 | 0.15 | 0.21 | 0.00 | 0.01 | 0.01 | 0.07 | 0.20 | 0.67 | 0.04 |
Operating CF/Net income |
0.67 | 0.77 | 1.09 | 0.82 | 0.41 | (0.07) | 0.86 | 1.24 | 0.96 | (4.84) |
Capex/Depreciation |
(3.89) | (4.51) | (0.60) | (0.38) | (0.38) | (1.34) | (4.90) | (0.50) | (0.12) | 0.00 |
Interest Coverage |
(65.58) | (36.17) | (28.96) | (50.21) | (57.23) | (148.18) | (106.40) | — | (27.84) | (9.99) |
| (33.58%) | (38.00%) | (42.46%) | (74.04%) | (55.97%) | (57.78%) | (114.96%) | (187.61%) | (273.57%) | 112.01% | |
| (26.71%) | (27.20%) | (34.24%) | (59.86%) | (41.12%) | (34.34%) | (41.44%) | (37.24%) | (27.17%) | 16.27% | |
ROIC |
0.00% | 0.00% | (123.30%) | (153.09%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (753.70%) |
Return on Tangible Assets |
(38.40%) | (35.68%) | (39.34%) | (117.02%) | (33.63%) | (41.23%) | (67.70%) | (61.32%) | (46.83%) | 81.64% |
Average Days of Receivables |
38.05 | 1.99 | 1.18 | 6,724.52 | 12.82 | 44.64 | 99.96 | 4.97 | 29.49 | 645.16 |
Research and Development Expense of Revenue |
449.28% | 230.98% | 165.14% | 8,689.93% | 2,313.49% | 1,806.64% | 470.48% | 209.87% | 62.70% | 810.18% |
Selling, General and Administrative Expense of Revenue |
163.46% | 82.22% | 73.27% | 3,867.29% | 1,157.02% | 931.94% | 233.49% | 121.95% | 37.46% | 601.22% |
Intangible Assets out of Total Assets |
0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 |
Share Based Compensation of Revenue |
62.13% | 28.56% | 27.23% | 985.12% | 263.11% | 335.49% | 67.19% | 19.53% | 6.14% | (19.53%) |
Graham Net Nets |
0.45 | 0.24 | 0.36 | 0.50 | 0.38 | 0.26 | 0.03 | (0.24) | (0.34) | (15.59) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(24.03%) | (11.82%) | (17.91%) | (109.17%) | (17.63%) | (26.67%) | (61.08%) | (73.83%) | (50.00%) | (2,166.67%) |
Free Cash Flow Yield |
(20.90%) | (12.62%) | (19.48%) | (91.76%) | (7.36%) | 0.33% | (63.73%) | (96.65%) | (52.13%) | (2,380.45%) |
Revenue per Share |
0.20 | 0.43 | 0.61 | 0.01 | 0.03 | 0.04 | 0.17 | 0.30 | 0.71 | 0.02 |
Operating CF per Share |
(0.68) | (0.62) | (1.07) | (1.07) | (0.38) | 0.07 | (0.88) | (0.70) | (0.27) | (0.46) |
Capex per Share |
(0.18) | (0.28) | (0.05) | (0.03) | (0.02) | (0.06) | (0.18) | (0.02) | (0.01) | 0.00 |
Free Cash Flow per Share |
(0.86) | (0.90) | (1.12) | (1.10) | (0.40) | 0.01 | (1.06) | (0.72) | (0.28) | (0.46) |
Cash per Share |
2.56 | 2.37 | 2.11 | 0.85 | 2.58 | 2.37 | 1.27 | 0.73 | 0.60 | 0.10 |
Shareholders Equity per Share |
2.35 | 2.31 | 2.54 | 1.18 | 2.40 | 1.32 | 0.51 | 0.20 | 0.05 | 0.12 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.35 | 2.31 | 2.54 | 1.18 | 2.40 | 1.32 | 0.51 | 0.20 | 0.05 | 0.12 |
Free Cash Flow |
(60.95) | (78.78) | (109.10) | (115.58) | (56.50) | 1.95 | (171.51) | (145.76) | (71.02) | (121.96) |
Working Capital |
158.48 | 155.87 | 206.66 | 86.15 | 359.08 | 352.92 | 190.87 | 134.76 | 122.19 | 23.08 |
Capital Expenditures |
(12.78) | (24.46) | (4.71) | (3.07) | (2.91) | (8.78) | (29.74) | (4.88) | (1.90) | (0.05) |
Net Current Asset Value |
130.38 | 152.02 | 201.24 | 62.58 | 288.24 | 151.87 | 8.33 | (35.55) | (46.34) | 13.92 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.90 | 0.65 | 0.08 | 2.74 | 0.73 | 1.43 | 1.10 | 0.08 | 0.01 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.12 | 0.13 | 0.22 | 0.26 | 0.27 | 0.22 | 0.11 | 0.19 | 0.51 | 2.20 |
Cash ROIC |
(17.53%) | (19.16%) | (24.14%) | (48.94%) | (7.74%) | 0.33% | (55.90%) | (78.18%) | (33.05%) | (210.56%) |
Accounts Receivable Turnover |
2.34 | 44.88 | 299.02 | 0.11 | 0.38 | 13.80 | 6.63 | 14.60 | 23.42 | 0.48 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | — | — | — | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | — | — | — | 0.00 | — |
Average Receivables |
6.08 | 0.84 | 0.20 | 10.43 | 10.41 | 0.45 | 4.09 | 4.13 | 7.60 | 12.43 |
Average Payables |
19.07 | 9.86 | 6.23 | 5.22 | 6.37 | 7.25 | 6.43 | 6.44 | 24.56 | 28.80 |
Average Assets |
267.94 | 257.83 | 278.94 | 229.14 | 316.34 | 460.34 | 399.23 | 305.77 | 264.52 | 154.89 |
Average Common Equity |
213.17 | 184.56 | 224.93 | 185.26 | 232.43 | 273.59 | 143.92 | 60.70 | 26.27 | 22.50 |
Columns are period end dates